COVID-19 Clearinghouse

COVID Banner

This page will house centralized content on COVID-19. Our aim is to make this page accessible and easy to navigate all the different resources on COVID-19 research, clinical trials, literature, reviews, etc. Specifically, we are focusing our interests on antiviral therapies. We are continuing to provide up-to-date information on ongoing trials, resources, treatments, and information regarding COVID-19. 

We hope to make this site as up-to-date and interactive as possible. If you have information regarding current or previous clinical trials involving anti-viral treatments and COVID-19, please share it with us. 

Disclaimer: This online resource does not provide medical advice and is intended for informational purposes only. It is not a substitute for professional medical advice, diagnosis or treatment. This information should never replace professional medical advice or replace seeking treatment with a certified care provider.

Last Updated: May 25, 2020

 

Remdesivir

Drug Description
Monophosphoramidate prodrug (Yethindra 2020)
Inhibits CoVs at early stages in replication by inhibiting viral RNA synthesis (Yethindra 2020)
In mouse, prophylactic treatment and therapeutic treatment with GS-5734 decreased viral lung titers improved pulmonary function and symptoms in SARS-CoV (Sheahan et al 2017)
Treating in elevating concentrations of GS-5734 may reduce levels of viral RNA associated with reduction of titer (Sheahan et al 2017)

Broad spectrum antiviral nucleotide prodrug with potent in vitro antiviral activity against a diverse panel of RNA viruses such as Ebola Virus (Sheahan et al 2020)

  • Mechanism likely through premature termination of viral RNA transcription as shown in biochemical assays using recombinant EBOV, NiV, and RSV polymerases 
  • Primary human lung epithelial cell cultures, RDV potently antiviral against circulating contemporary CoVs, SARS-CoV (EC50 = 0.07 uM), MERS-CoV (EC50 = 0.07 uM)

 

 

Clinical Trials
Name of Study Intervention Location Description Progress

Adaptive COVID-19 Treatment Trial


Phase 3

Remdesivir Several sites throughout the United States, Republic of Korea, and Singapore The study is a multicenter trial that will be conducted in up to 50 sites globally. The study will be a series of 2-arm comparisons between different investigational therapeutic agents and a placebo. There will be interim monitoring to introduce new arms and allow early stopping for futility, efficacy, or safety. If one therapy proves to be efficacious, this treatment will then become the control arm for comparison(s) with new experimental treatment(s). Start Date: February 21, 2020

Antiviral Therapy and Baricitinib for the Treatment of Patients with Moderate or Severe COVID-19


Phase 2

Remdesivir
Baricitinib
Hydroxychloroquine
Lopinavir/Ritonavir
Los Angeles County-USC Medical Center
USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
This phase II trial studies how well antiviral therapy works when given in combination with baricitinib for the treatment of moderate or severe coronavirus disease-2019 (COVID-19). Antiviral therapy such as hydroxychloroquine, lopinavir/ritonavir, and remdesivir may act against infections caused by the virus responsible for COVID-19. Baricitinib may reduce lung inflammation and help prevent the need for being placed on a ventilator should the disease worsen. Giving antiviral therapy in combination with baricitinib may reduce the risk of the disease from getting worse compared to antiviral therapy alone. Start Date: April 24, 2020
Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19. TCM prescriptions
antiviral drugs (i.e. IFN-α lopinavir/ritonavir, Ribavirin, Chloroquine Phosphate, Arbidol)
Jiangsu Famous Medical Technology Co., Ltd. This prospective multicenter cohort study observes the efficacy and safety of routine treatment + one or two of the following antiviral drugs + the following traditional Chinese medicine (TCM) regimens. Start Date: March 2, 2020

Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia


Phase 2,3

Hydrosychloroquine
Lopinavir/Ritonavir Pill
Azithromycin
Standard treatment
Multiple Locations in Bogota, Columbia   Start Date: May 11, 2020
Expanded Access Remdesivir (RDV; GS-5734™) Remdesivir   The treatment of communicable Novel Coronavirus (CODIV-19) of 2019 with Remdesivir (RDV; GS-5734™) also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)   
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection Remdesivir Gilead Sciences The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection. Start Date: April 2020

Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults


Phase 3

Remdesivir
Standard of care
Lopinavir/ritonavir
Interferon Beta-1A
Institut National de la Santé Et de la Recherche
Médicale, France
The primary objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19, the primary endpoint is the subject clinical status (on a 7-point ordinal scale) at day 15. Start Date: March 2020
Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections (REMDECO-19) Remdesivir Hôpital Cochin
Paris, France, 75014
This study is a retrospective cohort trial to assess the efficacy of remdesivir in hospitalized adult patients diagnosed with COVID-19. The study is a multicenter trial which will be carried out on different sites in France. This trial is retrospective and will analyze the data collected during treatment. Start Date: April 2020

Severe 2019-nCoV Remdesivir RCT


Phase 3

Remdesivir
Remdesivir placebo
Bin Cao Beijing
Beijing, China
Given the ready availability of remdesvir as a potential antiviral agent, based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with severe 2019-nCoV respiratory disease. Start Date: February 6, 2020

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment


Phase 3

Remdesivir vs. Standard of Care Gilead Sciences (Stanford (CA)
Newport Beach (CA)
Seattle (WA)
Everett (WA)
Hong Kong
South Korea
Singapore
Taiwan
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to the time to discharge in participants with moderate coronavirus disease (COVID-19). Start Date: March 15, 2020

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)


Phase 3

Remdesivir vs. Standard of Care Gilead Sciences (Stanford (CA)
Newport Beach (CA)
Seattle (WA)
Everett (WA)
Hong Kong
South Korea
Singapore
Taiwan
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to the normalization of temperature and oxygen saturation through Day 14 in participants with severe coronavirus disease (COVID-19). Start Date: March 6, 2020

The Efficacy of Different Anti-viral Drigs in COVID 19 Infected Patients


Phase 2,3

Remdesivir
Hydroxychloroquine
SoC
Andreas Barratt-Due
Oslo, Norway, 0756
The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and standard of care in hospitalized adult patients diagnosed with COVID-19. This trial will follow the core WHO protocol but has additional efficacy, safety and explorative endpoints. Start Date: March 25, 2020

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)


Phase 2

Lopinavir/Ritonavir Sunnybrook Health Sciences Centre This adaptive, randomized, open-label, controlled clinical trial evaluates the safety and efficacy of lopinavir/ritonavir combination treatment on COVID-19. Start Date: March 18, 2020

Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)


Phase 3

Remdesivir
Lopinavir/ritonavir
Interferon Beta-1A
Hydroxychloroquine
Standard of care
Institut National de la Santé Et de la Recherche
Médicale, France
The primary objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19. Start Date: March 22, 2020
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study
hydroxychloroquine
azithromycin
remdesivir
baricitinib
tocilizumab
sarilumab
lopinavir/ritonavir
oseltamivir
Centre Hospitalier Intercommunal Robert Ballanger Aulnay-sous-Bois, France    Centre Hospitalier Intercommunal Le Raincy-Montfermeil Montefermeil, France Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, we retrospectively analyzed associations between specific treatments, including but not limited to hydroxychloroquine, azithromycin, remdesivir, baricitinib, tocilizumab, sarilumab, lopinavir/ritonavir and oseltamivir; and clinical outcomes including, death and mechanical ventilation. Start Date: March 14, 2020
Publications
Title Authors Journal Date PID Summary
Rapid review for the anti-coronavirus effect of remdesivir. Ziyi Li, Xiaojie Wang, Donglin Cao, Ruilin Sun, Cheng Li, Guowei Li Drug Discovery Therapy 2020 32378648 Summarizes the potential use of remdesivir in the treatment of COVID-19. Dicusses the safety of remdesivir in humans. 
Early Experience With Remdesivir in SARS-CoV-2 Pneumonia
 
Durante-Mangoni E., et al. Infection May 16, 2020 32418190 We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19.
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Wang Y., et al. The Lancet April 29, 2020 32423584 In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.
Remdesivir for the Treatment of Covid-19 — Preliminary Report Beigel J. H., et al. The New England Journal of Medicine May 22, 2020   We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement.
Compassionate Use of Remdesivir for Patients With Severe Covid-19
 
Grein J, et al. The New England Journal of Medicine April 10, 2020 32275812  In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%).

 

Lopinavir/Ritonavir

Drug Description
Clinical trails show no efficacy 
Protease inhibitor antiviral therapy (Sheahan et al 2020)
anti-HIV drug combination of lopinavir and ritonavir - mainly targets protease during the process of producing new copies of HIV and coronavirus slash proteins using protease enzyme (Sheahan et al 2020)
Human immunodeficiency virus (HIV-1) protease inhibitor that is usually combined with ritonavir (RTV) to increase lopinavir half-life through the inhibition of cytochrome P450 (Sheahan et al 2020)

Binding analysis of the main SARS coronavirus proteinase with LPV showed that half of lopinavir is left outside of the catalytic site and the efficacy of lopinavir may be poor (Yao et al 2020)

  • 50% effective inhibitory concentration of LPV for the plaque reduction is 6 ug/ml in the Vero cell line 
Clinical Trials
Name of Study Intervention Location Description Progress

A Prospective/Retrospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia

Phase 4

Abidol hydrochloride
Oseltamivir,
Lopinavir/ritonavir
Department and Institute of Infectious Disease
Wuhan, Hubei, China
In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. Start Date: February 1, 2020
A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia ASC09F+Oseltamivir
Ritonavir+Oseltamivir
Oseltamivir
Department and Institute of Infectious Disease
Wuhan, Hubei, China
Based on oseltamivir treatment, evaluate the efficacy and safety of ASC09/ritonavir compound tablets(ASC09F) or ritonavir tablets for 2019-nCoV infection patients. Start Date: February 1, 2020

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial (DIC) 

Phase 4

Hydroxychloroquine
 Lopinavir / Ritonavir
 Interferon Beta-1A
Interferon Beta-1B
Shahid Beheshti University of Medical Sciences The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Start Date: April 10, 2020

Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT) 

Phase 2,3

Chloroquine or Hydroxychloroquine
Lopinavir/Ritonavir
Rivaroxaban
Thromboprophylaxis
Candesartan
non-RAS blocking antihypertensives
Clazakizumab
placebo
Medical University of Vienna The Austrian Coronavirus Adaptive Clinical Trial (ACOVACT) is a randomized, controlled, multicenter, open-label basket trial that aims to compare various antiviral treatments for COVID-19.  Start Date: April 16, 2020

Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers (COVIDAXIS) 

Phase 3

Hydroxychloroquine
Placebo
Lopinavir and ritonavir
Centre Hospitalier Universitaire de Saint Etienne The COVIDAXIS trial evaluates a chemoprophylaxis of SARS-CoV-2 infection in Health Care Workers. Start Date: April 14, 2020
Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19. TCM prescriptions
antiviral drugs (i.e. IFN-α lopinavir/ritonavir, Ribavirin, Chloroquine Phosphate, Arbidol)
Jiangsu Famous Medical Technology Co., Ltd. This prospective multicenter cohort study observes the efficacy and safety of routine treatment + one or two of the following antiviral drugs + the following traditional Chinese medicine (TCM) regimens. Start Date: March 2, 2020

Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19 (Covid-19HUF) 

Phase 2

Lopinavir/ritonavir
 hidroxicloroquine,
imatinib tablets
baricitinib oral tablet
Hospital Universitario de Fuenlabrada The study aims to compare lopinavir / ritonavir (200 /50), imatinib 400mg, baricitinib 4mg, in combination with hydroxychloroquine 200mg, administered for 7 days in the setting of SARS-CoV-2 pneumonia treatment. Start Date: April 13, 2020
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection   Hyperimmune plasma
Hidroxicloroquina + Azitromicina
 Lopinavir/ritonavir + Interferon β-1b + Hidroxicloroquina 
Hospital Unversitario Virgen Macarena 
Sevilla, Spain
Phase I / II multicentre, randomized and controlled clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection. Start Date: April 2020

Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease 

Phase 2

Lopinavir/ritonavir
Hydroxychloroquine sulfate
Asan Medical Center,
University of Ulsan College of Medicine     
Seoul, Korea
This study investigates whether lopinavir/ritonavir or hydroxychloroquine reduces viral load from respiratory specimens in patients with mild COVID-19. Start Date: March 11, 2020

COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 (COVIDMED) 

Phase 2,3

lopinavir/ritonavir
Hydroxychloroquine Sulfate
 Losartan
Placebos
Bassett Healthcare This pragmatic adaptive trial compares outcome in COVID-19 patients treated with lopinavir/ritonavir, hydroxychloroquine, losartan, and placebo. Start Date: April 6, 2020

COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir (CORIPREV-LR) 

Phase 3

Lopinavir/Ritonavir St. Michael's Hospital, Toronto This is a cluster randomized controlled trial (RCT) of oral LPV/r as PEP against COVID-19, that will address the immediate need for preventive interventions, generate key data on COVID-19 transmission, and serve as a research platform for future vaccines and preventive agents. Start Date: March 30, 2020
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia Hydroxychloroquine
Lopinavir/Ritonavir
Azithromycin
SoC 
Multiple sites in Columbia Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab). Clinical trials offer conflicting evidence regarding the effectiveness and safety of therapies The real effectiveness and safety profile of the treatments for COVID-19 remains unknown. Start Date: May 11, 2020

Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection
​​​​​

Phase 4

Danoprevir+Ritonavir Huoshenshan Hospital Evaluation of the efficacy and safety of Danoprevir sodium tablet combined with ritonavir for SARS-CoV-2 infected patients. Start Date: March 18, 2020
Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland (COPEP) Hydroxychloroquine Sulfate
 Lopinavir/ritonavir 
Universitätsspital Basel and SwissTPH
Basel, Switzerland   
Hôpitaux Universitaires de Genève
Geneva, Switzerland
A study to assess, in a three-arm open-label cluster randomized clinical trial, the efficacy of a single-dose of HCQ treatment and of a 5-day course of LPV/r treatment in preventing COVID-19 in asymptomatic individuals exposed to a SARS-CoV-2 documented index patient, compared to surveillance alone. Start Date: April 2020
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection ASC09/ritonavir
lopinavir/ritonavir 
First Affiliated Hospital of Zhejiang University Based on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in patients with 2019-nCoV pneumonia. Start Date: February 7, 2020

Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 

Phase 2,3

Levamisole Pill + Budesonide+Formoterol inhaler
 Lopinavir/Ritonavir + hydoxychloroquine
Fasa University of Medical Sciences This study evaluates the safety and efficacy a new strategy for treatment of COVID-19 which consists of local anti- inflammatory and systemic immune stimulant drugs. Start Date: March 31, 2020

Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection 

Phase 4

Ganovo + ritonavir +/-Interferon nebulization The Ninth Hospital of Nanchang
Nanchang, Jiangxi, China
Given no specific antiviral therapies for new coronavirus pneumonia approved yet and Ganovo, an oral Hepatitis C virus protease inhibitor, approved in China in June 2018 , this open, controlled trial will evaluate the efficacy and safety of Ganovo in hospitalized patients infected with 2019-nCoV. Start Date: February 17, 2020

Interferon Beta 1a in COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial (IB1aIC) 

Phase 4

Interferon Beta-1A
Lopinavir/Ritonavir
 Single Dose of Hydroxychloroquine
Shahid Beheshti University of Medical Sciences The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Start Date: April 15, 2020

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment 

Phase 2

Lopinavir/ritonavir, Ribavirin, Interferon Beta-1B University of Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
A combination of lopinavir/ ritonavir, ribavirin and interferon beta-1b will expedite the recovery, suppress the viral load, shorten hospitalisation and reduce mortality in patients with 2019-n-CoV infection compared with to lopinavir/ ritonavir Start Date: February 10, 2020
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe) Lopinavir / ritonavir tablets
Xiyanping injection
Jiangxi Qingfeng Pharmaceutical Co. Ltd. This study is a Randomized, Parallel Controlled Clinical Study to treat patients with COVID-19 infection to observe the efficacy and safety of liponavir/ritonavir antiviral treatment combined with Xiyanping injection. Start Date: March 14, 2020
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome (OUTCOV) Azithromycin
 Hydroxychloroquine
 Lopinavir 200Mg/Ritonavir 50Mg  
Multiple sites in France Our primary objective is to evaluate the efficacy of early outpatient treatment compared to standard of care in patients COVID-19 with risk factors for poor outcome. The criteria is hospital admission at Day 20 and the hospital admission rate will be compared between groups by a Chi² test or a Fisher's exact test.  Start Date: April 28, 2020

Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 (PROTECT-Surg)

Phase 3

Lopinavir-Ritonavir
Hydroxychloroquine
  The aim of this study is to reduce COVID-19 related pulmonary complications in adult patients undergoing all types of elective or emergency surgery in a COVID-19 exposed environment. A Trial in Low and Middle Income Countries (LMICs) and A Trial in High Income Countries (HICs) Start Date: May 15, 2020 

Randomized Evaluation of COVID-19 Therapy

Phase 2,3

Lopinavir-Ritonavir
Corticosteroid
Hydroxychloroquine
Azithromycin
Tocilizumab
Nuffield Department of Population Health, University of Oxford  Oxford, United Kingdom RECOVERY is a randomised trial investigating whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin or Tocilizumab prevents death in patients with COVID-19 Start Date: March 19, 2020
The Clinical Study of Carrimycin on Treatment Patients With COVID-19 Carrimycin
lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate 
  A multicenter, randomized (1:1), open-controlled (one of lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate) study" . We try to establish the criteria for clinical cure and the early predictive model of COVID-19 progression.  Start Date: February 23, 2020

Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

Phase 2

Liponavir/Ritonavir
hydroxychloroquine sulfate
baricitinib
sarilumab
Nova Scotia Health Authority    
Halifax, Nova Scotia, Canada
Investigational medications adjunct to clinical standard of care treatment will be assessed to evaluate safety and effectiveness as an anti-COVID-19 treatment Start Date: April 2020

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO) 

Phase 2

Lopinavir/Ritonavir Sunnybrook Health Sciences Centre This adaptive, randomized, open-label, controlled clinical trial evaluates the safety and efficacy of lopinavir/ritonavir combination treatment on COVID-19. Start Date: March 18, 2020

Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 (TREAT NOW) 

Phase 2

Lopinavir/ritonavir
hydroxychloroquine
placebo
University of Colorado School of Medicine Aurora, Colorado, United States
Beth Israel Deaconess Medical Center Boston Massachusetts, United States
Vanderbilt University Medical Center Nashville, Tennessee, United States
Blinded, multicenter, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine vs lopinavir/ritonavir vs placebo in early outpatient treatment of adults with COVID-19 Start Date: May 1, 2020

Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy) 

Phase 4

Remdesivir
Lopinavir/ritonavir
Interferon Beta-1A
Hydroxychloroquine
Standard of care
Institut National de la Santé Et de la Recherche Médicale, France The primary objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19. Start Date: March 22, 2020

Umifenovir in COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial (UAIIC) 

Phase 4

Umifenovir
Interferon-β 1a
Lopinavir / Ritonavir
Single Dose of Hydroxychloroquine
Standards of Care
Shahid Beheshti University of Medical Sciences The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Start Date: April 15, 2020

Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial 

Phase 3

Oseltamivir
Chloroquine
Lopinavir
Ritonavir
Favipiravir
Oseltamivir
Darunavir
Thailand, Rajavithi Hospital A 6-Week Prospective, Open label, Randomized, in Multicenter Study evaluating the efficacy and safety of various combinations of protease inhibitors in the treatment of COVID-19. Start Date: March 15, 2020
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia Xiyanping injection
Lopinavir/ritonavir
alpha-interferon nebulization
Jiangxi Qingfeng Pharmaceutical Co. Ltd. Investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of Xiyanping injection in patients with 2019-nCoV pneumonia. Start Date: February 14, 2020
Publications
Title Authors Journal Date PID Summary
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 Bin Cao, M.D., Yeming Wang, M.D., Danning Wen, M.D., Wen Liu, M.S., et al. The New England Journal of Medicine May 7, 2020 32187464 We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir–ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. 

Chloroquine/Hydroxychloroquine 

Drug Description
Chloroquine
Known to suppress immune activation by a number of mechanisms, including inhibition of intracellular toll-like receptor (TLR) signaling and inflammatory cytokine secretion (Murray et al 2010)

In vitro, shown to reduce HIV infection-induced T-cell immune activation  (Murray et al 2010)

  • Decreased HLA-DR+ CD-38+ CD8 memory T cells in CQ-treated subjects
  • Administration of CQ resulted in decreased immune activation as measured by parameter closely correlated with disease progression - suppresses key aspects of HIV disease pathogenesis that are correlated with disease progression
Antiretroviral effect on HIV-1 attributable to post-transcriptional inhibition of glycosylation of the gp120 envelope glycoprotein and neosynthesized virus particles are non-infectious (Devaux et al 2020)

 

Hydroxychloroquine
Shown to have some efficacy in mild disease
Less toxic than chloroquine
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

 

Clinical Trials
Name of Study Intervention Location Description Progress

A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)

Phase 4

Hydrozychloroquine Oregon Health and Science University
Portland, Oregon, United States
This is a prospective, randomized, participant-blinded, placebo-controlled, pilot study to assess the preliminary efficacy and safety of hydroxychloroquine for the treatment of patients with lower respiratory tract SARS-CoV-2 infection. Start Date: May 2020

A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients (OAHU-COVID19)

Phase 3

Hydroxychloroquine Queen's Medical Centre The overall objective is to evaluate the clinical efficacy and safety of hydroxychloroquine (HCQ) relative to standard of care among 350 hospitalized adult patients who have COVID-19. Start Date: March 26, 2020

A Real-life Experience on Treatment of Patients With COVID 19

Phase 2,3

Chloroquine
Favipiravir
Nitazoxanide
Ivermectin
Niclosamide
Tanta University COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin. April 15, 2020

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection (HELPCOVID-19)

Phase 2

Hydroxychloroquine
Vitamin C
Vitamin D
Zinc
ProgenaBiome This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent infection with COVID-19 Start Date: April 2020

A Study of Quintuple Therapy to Treat COVID-19 Infection (HAZDpaC)

Phase 2

Hydroxychloroquine
Azithromycin
Vitamin C
Vitamin D
Zinc
ProgenaBiome This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection). Start Date: April 2020

ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease

Phase 3

Hydroxychloroquine University of Calgary This double-blind placebo-controlled, randomized clinical trial will determine if hydroxychloroquine for 5 days, initiated within 96 hours of confirmation of a positive COVID-19 result, and within 12 days of symptom onset, reduces the occurrence of severe COVID-19 disease. Start Date: April 13, 2020

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial (DIC)

Phase 4

Hydroxychloroquine
Lopinavir / Ritonavir
Interferon Beta-1A
Interferon Beta-1B
Shahid Beheshti University of Medical Sciences The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Start Date: April 10, 2020

Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial (ACT COVID19)

Phase 3

Azithromycin
Chloroquine
Population Health Research Institute ACT is a randomized clinical trial to assess therapies to reduce the clinical progression of COVID-19. Start Date: April 1, 2020

Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+) (COVID+PA)

Phase 4

Hydroxychloroquine
Azithromycin
Abderrahmane Mami Hospital The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomatic patients with ou without co-morbidities Start Date: April 15, 2020

Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals (COVID_2Pro)

Phase 3

Hydroxychloroquine Abderrahmane Mami Hospital Interventional, Multicentric, Randomized Controlled Study in Two Parallel Groups of 530 Healthcare Professionals working in the Intensive Care Unit Exposed to Risk of COVID19 Infection Taking Hydroxychloroquine (HCQ) (200 mg/day) VS Placebo Start Date: Apri 15, 2020

Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT)

Phase 2,3

Chloroquine or Hydroxychloroquine
Lopinavir/Ritonavir
Rivaroxaban
Thromboprophylaxis
Candesartan
non-RAS blocking antihypertensives
Clazakizumab
Medical University of Vienna The Austrian Coronavirus Adaptive Clinical Trial (ACOVACT) is a randomized, controlled, multicenter, open-label basket trial that aims to compare various antiviral treatments for COVID-19.  Start Date: April 16, 2020

Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial (AZIQUINE-ICU)

Phase 3

Azithromycin
Hydroxychloroquine
Placebo
Frantisek Duska
Charles University
Czech Republic
A trial in which we test a hypothesis, that early administation of hydrochlorochine alone or in combination with azithromycin can prevent respiratory deterioration in patients admitted to intensive care due to rapidly progressive COVID-19 infection. Start Date: April 20, 2020

Azithromycin in Hospitalized COVID-19 Patients

Phase 4

Hydroxychloroquine
Azithromycin
Shahid Modarres Hospital
Shahid Beheshti University of Medical Sciences and Health Services 
Tehran, Iran, Islamic Republic of 
The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. Start Date: April 20, 2020

Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers (COVIDAXIS)

Phase 3

Hydroxychloroquine
Lopinavir and ritonavir
Centre Hospitalier Universitaire de Saint Etienne The COVIDAXIS trial evaluates a chemoprophylaxis of SARS-CoV-2 infection in Health Care Workers. Start Date: April 14, 2020

Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID

Phase 2

Chloroquine Columbia University The primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVID-19 in preventing symptomatic COVID-19 infections. April 2020

ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020 (QUARANTINE2020)

Phase 4

Chloroquine phosphate
Telemedicine
Wroclaw Medical University The aim of the study is to evaluate whether the therapy with chloroquine phosphate (CQ, in combination with telemedical approach) in addition to standard care is effective and safe in reducing composite endpoint of COVID-19-related hospitalization or all cause death. Start Date: April 6, 2020

Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2 (CloroCOVID19)

Phase 2

Chloroquine diphosphate Fundação de Medicina Tropical The investigators intend to investigate the efficacy and the safety of CQ diphosphate in the treatment of hospitalized patients with severe acute respiratory syndrome in the scenario of SARS-CoV2. Start Date: March 23, 2020

Chloroquine for Mild Symptomatic and Asymptomatic COVID-19

Phase 2,3

Chloroquine
standard care
HaEmek Medical Center, Israel The purpose of this study is to test whether a low dose of Chloroquine will reduce the duration of the viral shedding and prevent the disease from worsening. Start Date: April 2020

Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19

Phase 3

Chloroquine or hydroxychloroquine Khayelitsha Hospital  Groote Schuur Hospital  
Cape Town, Western Cape, South Africa
The trial objective is to compare chloroquine (or hydroxychloroquine) versus standard of care for the primary endpoint of hospitalisation or death at 28 days. Consenting adults who meet criteria for a Covid-19 person under investigation and who are ≥18 years, known to be HIV-positive, not requiring immediate hospitalisation and are not at risk of cardiac toxicities related to the study drug will be enrolled.  Start Date: May 1, 2020

Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial (HOPE)

Phase 2

UNIKINON (Chloroquine phosphate) Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. The study aims to document possible prevention of pneumonia in patients staying at home and in improving the symptoms of SARS-CoV-2 pneumonia in patients who will be hospitalised. Start Date: April 6, 2020
Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV) Chloroquine University of Oxford The study is a double-blind, randomised, placebo-controlled trial that evaluates the efficacy and safety of chloroquine in the treatment of coronavirus disease 2019. Start Date: May 2020

Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19

Phase 4

Chloroquine Sulfate
Hydroxychloroquine
Standard supportive care

UMCU

Utrecht, Netherlands

Multicentre, cluster randomized cross-over, open label trial. Hospitals will be randomly allocated to one of 3 treatment arms in sequential periods of one week: chloroquine base versus hydroxychloroquine versus supportive care without any drug presumed active against SARS-COV-2. Patients will be treated based on the date of inclusion. Start Date: April 14, 2020
Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV) Chloroquine
Hydroxychloroquine
University of Oxford This study evaluates the safety and efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Start Date: April 2020

Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19 (TOCOVID)

Phase 2

Tocilizumab
Hydroxychloroquine
Azithromycin
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau This clinical trial is designed to evaluate the use of Tocilizumab in combination with hydroxychloroquine and azithromycin for the treatment of hospitalized adult patients with COVID-19. Start Date: April 2, 2020
Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19. TCM prescriptions
antiviral drugs (i.e. IFN-α lopinavir/ritonavir, Ribavirin, Chloroquine Phosphate, Arbidol)
Jiangsu Famous Medical Technology Co., Ltd. This prospective multicenter cohort study observes the efficacy and safety of routine treatment + one or two of the following antiviral drugs + the following traditional Chinese medicine (TCM) regimens. Start Date: March 2, 2020

Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19 (CLOCC)

Phase 4

Camostat Mesilate
Hydroxychloroquine
Heinrich-Heine University, Duesseldorf The primary objective of this study is to demonstrate, that a combination therapy of hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo in participants with moderate COVID-19. Start Date: June 1, 2020

Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease

Phase 2

Lopinavir/ritonavir
Hydroxychloroquine sulfate
 Asan Medical Center
University of Ulsan College of Medicine  
Seoul, Korea 
This study investigates whether lopinavir/ritonavir or hydroxychloroquine reduces viral load from respiratory specimens in patients with mild COVID-19. Start Date: March 11, 2020

Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study (CP-COVID-19)

Phase 2,3

Plasma
Hydroxychloroquine, Azithromycin
Universidad del Rosario The process is based on obtaining plasma from patients recovered from COVID-19 in Colombia, and through a donation of plasma from the recovered, the subsequent transfusion of this to patients infected with coronavirus disease (COVID-19). Start Date: April 1, 2020

COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 (COVIDMED)

Phase 2,3

lopinavir/ritonavir
Hydroxychloroquine Sulfate
Losartan
Bassett Healthcare This pragmatic adaptive trial compares outcome in COVID-19 patients treated with lopinavir/ritonavir, hydroxychloroquine, losartan, and placebo. Start Date: April 6, 2020

CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION (CROWN CORONA)

Phase 2

Chloroquine
Hydroxychloroquine
Placebo
Washington University School of Medicine The trial will evaluate which of the intervention arms is most effective at decreasing the incidence of severe COVID-19 disease, without unacceptable side effects or safety events. Start Date: April 2020

Double Therapy With IFN-beta 1b and Hydroxychloroquine

Phase 2

Interferon Beta-1B
Hydroxychloroquine
The University of Hong Kong We propose to conduct an open-label randomized controlled trial on a short course of interferon β-1b and hydroxychloroquine combination treatment for patients hospitalized for COVID-19 infection. Start Date: April 9, 2020
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia
 
Phase 2,3
Hydroxychloroquine
Lopinavir/Ritonavir
Azithromycin
SoC
Multiple sites in Columbia Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab). Clinical trials offer conflicting evidence regarding the effectiveness and safety of therapies The real effectiveness and safety profile of the treatments for COVID-19 remains unknown. Start Date: May 11, 2020

Effectiveness of Hydroxychloroquine in Covid-19 Patients (Covid)

Phase 3

Hydroxychloroquine
Azithromycin
Ayub Medical College, Abbottabad A single centered, single-blind randomized control trial study to find the effectiveness of hydroxychloroquine alone and adjuvant with azithromycin in mild to severe Covide-19 pneumonia patients. Start Date: March 28, 2020

Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19

Phase 1

Hydroxychloroquine Sulfate
Azithromycin
Azidus Brasil This is an exploratory, open label, multi-center study to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (AZT) to treat moderate to severe COVID-19 pneumonia. Start Date: April 3, 2020

Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )

Phase 3

Hydroxychloroquine Shanghai Public Health Clinical Center
Shanghai, China
There is no vaccine or antiviral treatment for human coronavirus, so this study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of pneumonia caused by the 2019 novel coronavirus. Start Date: February 6, 2020

Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19

Phase 4

Hydroxychloroquine Sulfate 200 MG Taoyuan General Hospital, Ministry of Health and Welfare   Taoyuan City, Taiwan This is a multi-center, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of Hydroxychloroquine Sulfate (HCQ) in adult Patients with mild to moderate coronavirus disease (COVID-19) compared to standard of care treatment (SOC). Start Date: April 1, 2020
Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients (MG-COVID)
 
Phase 3

Hydroxychloroquine and Azithromycin

Azinc

  The main objective is to assess the efficacy of Hydroxychloroquine combined with azithromycin in COVID-19 patients in primary care, in add-on to standard of care, on unfavorable outcome defined by the onset of at least one of the following between D0 and D14: hospitalization, death or percutaneous O² saturation ≤ 92% in ambient air.  Start Date: May 1, 2020
Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland (COPEP)
 
Hydroxychloroquine Sulfate
Lopinavir/ritonavir
Universitätsspital Basel and SwissTPH
Basel, Switzerland    
Hôpitaux Universitaires de Genève
Geneva, Switzerland
A study to assess, in a three-arm open-label cluster randomized clinical trial, the efficacy of a single-dose of HCQ treatment and of a 5-day course of LPV/r treatment in preventing COVID-19 in asymptomatic individuals exposed to a SARS-CoV-2 documented index patient, compared to surveillance alone. Start Date: April 2020

Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19

Phase 2,3

Levamisole Pill + Budesonide+Formoterol inhaler, Lopinavir/Ritonavir + hydoxychloroquine Fasa University of Medical Sciences This study evaluates the safety and efficacy a new strategy for treatment of COVID-19 which consists of local anti- inflammatory and systemic immune stimulant drugs. Start Date: March 31, 2020

EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA (TEACHCOVID)

Phase 3

 
Hydroxychloroquine and azithromycin
Hydroxychloroquine
  This study wants to evaluate the clinical impact of adding Azithromycin to Hydroxychloroquine in the treatment of Sars-CoV-2 pneumonia  Start Date: May 1, 2020
Favipiravir in Hospitalized COVID-19 Patients (FIC)
 
Phase 4
Favipiravir
Hydroxychloroquine
Shahid Modarres Hospital
Shahid Beheshti University of Medical Sciences and Health Services 
Tehran, Iran, Islamic Republic of
The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. Start Date: April 20, 2020

HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers

Phase 3

Hydroxychloroquine Medical University of Vienna To demonstrate the efficacy of low-dose hydroxychloroquine as primary prevention in healthcare workers Design, participants and interventions: Prospective, randomized, parallel group, double-blinded, placebo controlled, study. Start Date: April 2020

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ)

Phase 3

Hydroxychloroquine Duke University This is a double blind, placebo controlled study in approximately 15,000 health care workers at risk for being exposed to COVID-19 to evaluate the efficacy of hydroxychloroquine in the treatment of COVID-19.  Start Date: April 2020

High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19

Phase 1

Hydroxychloroquine University of Chicago Our hypothesis is that targeting high risk patients earlier in the disease course and with a higher dose regimen are both required to see improvement in disease outcome measures in COVID-19. This study aims to prove the tolerability of high dose HCQ in this setting. Start Date: April 2020

Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers

Phase 2

Hydroxychloroquine Sulfate (HCQ) Hackensack Meridian Health The study proposes to conduct an open-label Phase II trial to evaluate the feasibility, safety and early efficacy of hydroxychloroquine (HCQ) administration in reduction of transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and development of Corona Virus Disease 2019 (COVID-19) in high-risk, healthy acute care provider participants exposed, directly or indirectly, to COVID-19 patients. Start Date: April 14, 2020

Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)

Phase 3

Hydroxychloroquine Gangnam Severance Hospital In this study, we aim to evaluate the efficacy and safety of hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2. Start Date: April 1, 2020

Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) (PHYDRA)

Phase 3

Hydroxychloroquine National Institute of Respiratory Diseases, Mexico Triple blinded, phase III randomized controlled trial with parallel groups (200mg of hydroxychloroquine per day vs. placebo) aiming to prove hydroxychloroquine's security and efficacy as prophylaxis treatment for healthcare personnel exposed to COVID-19 patients. Start Date: April 1, 2020

Hydroxychloroquine for COVID-19 (COV-HCQ)

Phase 3

Hydroxychloroquine Sulfate University Hospital Tuebingen We propose to conduct a placebo-controlled trial in COVID-19 patients with mild to moderate disease in Germany to assess virological efficacy, tolerability and safety of hydroxychloroquine in the treatment of COVID-19.  Start Date: March 29, 2020

Hydroxychloroquine for COVID-19 PEP

Phase 1

Hydroxychloroquine Sulfate
Ascorbic Acid
University of Washington This is a randomized, multi-center, placebo-equivalent (ascorbic acid) controlled, blinded study of Hydroxychloroquine (HCQ) post-exposure prophylaxis (PEP) for the prevention of SARS-CoV-2 infection in adults exposed to the virus. Start Date: March 2020

Hydroxychloroquine for the Treatment of Mild COVID-19 Disease

Phase 3

Hydroxychloroquine University Hospital Tuebingen The aim of this placebo-controlled trial is to assess the effect of hydroxychloroquine on duration of symptoms in mild COVID-19 patients and time of virus shedding as an important tool to reduce the risk of further community transmissions.  Start Date: April 10, 2020

Hydroxychloroquine for the Treatment of Mild COVID-19 Disease (COMIHY)

Phase 3

Hydroxychloroquine University Hospital Tuebingen The aim of this placebo-controlled trial is to assess the effect of hydroxychloroquine on duration of symptoms in mild COVID-19 patients and time of virus shedding as an important tool to reduce the risk of further community transmissions.  Start Date: April 10, 2020

Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death

Phase 1

Hydroxychloroquine Rambam Health Care Campus The objective of this trial is to evaluate the efficacy of HCQ in patients with newly diagnosed COVID-19 who have mild to moderate disease or at risk for complications. Start Date: March 2020
Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients HCQ & AZ vs HCQ+SIR King Hussein Cancer Center 
Amman, Jordan
The evidence for using sirolimus for influenza is emphasized by a RCT that showed reduction of mechanical ventilation time by 50% (7 days on sirolimus arm vs 15 days on oseltamivir/steroids arm). Safe administration in human subjects is illustrated by multiple phase I/II clinical trials, performed in patients with cancer. COVID19-HOPE trial will randomize patients to 2 arms: HCQ/AZ (Arm A) and HCQ/SIR (Arm B). Start Date: May 1, 2020

Hydroxychloroquine in Outpatient Adults With COVID-19

Phase 1

Hydroxychloroquine SAR321068 Sanofi To assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral load in outpatient adults with COVID-19 Start Date: March 31, 2020

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

Phase 4

Hydroxychloroquine
Vitamin C
Providence Health & Services This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19. Start Date: March 30, 2020

Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers

Phase 2

Hydroxychloroquine Baylor Research Institute This study assesses the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection. Start Date: April 3, 2020

Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)

Phase 2,3

Hydroxychloroquine Columbia University The purpose of this study is to test the hypothesis that post-exposure prophylaxis with hydroxychloroquine will reduce the symptomatic secondary attack rate among household contacts of known or suspected COVID-19 patients. Start Date: March 2020

Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA)

Phase 3

Hydroxychloroquine National Institute of Respiratory Diseases, Mexico Double blinded randomized clinical trial designed to evaluate the security and efficacy of hydroxychloroquine as treatment for COVID-19 severe respiratory disease. Start Date: March 23, 2020

Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore

Phase 2

Hydroxychloroquine Montefiore Medical Center Given the high prevalence of COVID19 illness (both SARS-CoV-2 RT-PCR confirmed and highly suspect cases) among healthcare workers (HCW) within the Montefiore Health System (MHS), hydroxychloroquine (HCQ) will be prescribed to healthcare workers who are at the highest risk for severe COVID19 illness. Start Date: April 2020

Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease (HYCOVID)

Phase 3

Hydroxychloroquine University Hospital, Angers The research hypothesis is that treatment with hydroxychloroquine improves prognosis and reduces the risk of death or use for invasive ventilation in patients with COVID-19. Start Date: April 2020

Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19

Phase 4

Nitazoxanide
Hydroxychloroquine
Materno-Perinatal Hospital of the State of Mexico The purpose of this study is to contrast the beneficial effect of NTZx vs NTZx plus hydroxychloroquine in patients Coronavirus Disease (COVID-19) as well as against other treatments. Start Date: April 6, 2020

Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS)

Phase 2

Hydroxychloroquine
Azithromycin
University of Utah This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating hospitalized patients with suspected or confirmed COVID-19. Start Date: March 30, 2020

Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT)

Phase 3

Hydroxychloroquine
Azithromycin
University of Utah
Utah Department of Health
This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating outpatients with suspected or confirmed COVID-19. Start Date: April 2, 2020
Hydroxychloroquine, Hydroxychloroquine, Azithromycin in the Treatment of SARS CoV-2 Infection (WU352) Hydroxychloroquine Sulfate
Azithromycin
Chloroquine Sulfate
Washington University School of Medicine This Phase III trial four treatment strategies non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection. Start Date: April 4, 2020

Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT (PROTECT)

Phase 3

Hydroxychloroquine
Oseltamivir
Azithromycin
University of Health Sciences Lahore To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate vs oseltamivir vs Azithromycin in the treatment of COVID-19. Start Date: April 7, 2020

Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19 (Chloroquine UN)

Phase 3

Hydroxychloroquine Universidad Nacional de Colombia This is a PILOT STUDY, a Phase III double-blind, randomized, placebo-controlled clinical study in which we assess the clinical effect of the prophylactic administration of hydroxychloroquine vs. placebo to healthcare workers working at our University Hospital (HUN). Start Date: April 20, 2020

Interferon Beta 1a in COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial (IB1aIC)

Phase 4

Interferon Beta-1A
Lopinavir/Ritonavir
Single Dose of Hydroxychloroquine
Shahid Beheshti University of Medical Sciences The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Start Date: April 15, 2020

Ivermectin Adjuvant to Hydroxychloroquin in COVID19 Patients

Phase 1

Ivermectine
Hydroxychloroquine Sulfate
Placebos
University of Baghdad Comparing the efficacy and safety of adjuvant use of Ivermectin in covid19 patients with pneumonia using Ivermectin with hydroxychloroquine compared to HCQ Start Date: April 8, 2020

Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (HCQINRLGII)

Early Phase 1

Hydroxychloroquine Sulfate
Bromhexine
Instituto Nacional de Rehabilitacion This study will investigate the security and efficacy of a daily low dose of hydroxychloroquine, in preventing the development of the disease from COVID-19 in Health Care Workers at a National Institute of Health In Mexico City. Start Date: April 10, 2020

Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study

Phase 2

Hydroxychloroquine United States Department of Defense A well-designed study to evaluate whether there is value in using Hydroxychloroquine or Chloroquine as a pre-exposure prophylaxis or post-exposure prophylaxis regimen for COVID-19 patients and at risk personnel. Start Date: April 2020

Norwegian Coronavirus Disease 2019 Study

Phase 4

Hydroxychloroquine Sulfate University Hospital, Akershus Aim to investigate the virological and clinical effects of chloroquine treatment in patients with established COVID-19 in need of hospital admission. Patients will be randomized in a 1:1 fashion to standard of care or standard of care with the addition of therapy with chloroquine. Start Date: March 23, 2020

Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease (ORCHID)

Phase 3

Hydroxychloroquine Massachusetts General Hospital ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19.  Start Date: April 2, 2020

Phase 2 Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection

Phase 2

Hydroxychloroquine
Azithromycin
Duke University This is a phase II, randomized, open-label, incomplete factorial with nested randomization clinical trial evaluating the efficacy and safety of two potential treatments for hospitalized patients with confirmed SARS-CoV-2 infection. Start Date: April 2020
Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds (PEACE)
 
Phase 4
Hydroxychloroquine Sulfate
Chloroquine
Placebo
Expo Covid Center
Mayo Hospital
Pakistan Kidney and Liver Institute  
Lahore, Punjab, Pakistan
To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients. Start Date: April 14, 2020

Post-exposure Prophylaxis for SARS-Coronavirus-2

Phase 3

Hydroxychloroquine University of Minnesota Minneapolis, Minnesota, United States Chloroquine or Hydroxychloroquine may have antiviral effects against SARS-COV2 which may prevent COVID19 disease or early preemptive therapy may ameliorate disease severity. This trial will use a modification of standard malaria dosing of hydroxychloroquine to provide post-exposure prophylaxis / preemptive therapy. Start Date: March 17, 2020

Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic (PrEP_COVID)

Phase 3

Hydroxychloroquine Barcelona Institute for Global Health The investigators aim to evaluate the efficacy of pre-exposure prophylaxis with hydroxychloroquine in healthcare workers with high-risk of SARS-CoV-2 infection. Start Date: April 3, 2020

Preventing COVID-19 in Healthcare Workers With HCQ: A RCT

Phase 2

Hydroxychloroquine
Vitamin C
Stony Brook University Healthcare workers (HCW) at risk of Covid-19 will have baseline serology for SARS-CoV-2 to see if they are already immune to Covid-19. HCW will get baseline assessment and if meeting inclusion criteria and no exclusion criteria they will be randomized in a 2:1 ratio to hydroxychloroquine or Vitamin C on a weekly basis for three months. Start Date: April 20, 2020
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 (PROTECT-Surg)
 
Phase 3
Lopinavir-Ritonavir
Hydroxychloroquine
   The aim of this study is to reduce COVID-19 related pulmonary complications in adult patients undergoing all types of elective or emergency surgery in a COVID-19 exposed environment. A Trial in Low and Middle Income Countries (LMICs) and A Trial in High Income Countries (HICs) Start Date: May 15, 2020

Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19 (ProPAC-COVID)

Phase 2

Azithromycin
Hydroxychloroquine
Placebo oral tablet
Chronic Obstructive Pulmonary Disease Trial Network, Denmark This is a randomized, placebo-controlled, double-blinded multi-center trial evaluating the effect of azithromycin and hydroxychloroquine treatment in patients with COVID-19 during hospitalization. Start Date: April 6, 2020
Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia Plaquenil 200Mg Tablet Istinye University Main purpose of the study was to cover participants those who are facing or treating COVID19 infected patients in Ankara. Start Date: March 20, 2020

PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds

Phase 4

Hydroxychloroquine
Chloroquine
Placebo
Expo Covid Isolation Center / Mayo Hospital Field Hospital 
Mayo Hospital / King Edward Medical University 
Pakistan Kidney and Liver Institute  Services Hospital 
Lahore, Punjab, Pakistan
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection. Start Date: Apri 15, 2020
Qatar Prospective RCT Of Therapy Eliminating Covid Transmission (Q-PROTECT) Hydroxychloroquine
Azithromycin
Placebo
Hamad Medical Corporation Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19. Start Date: April 14, 2020

Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS)

Phase 3

Emtricitabine/tenofovir disoproxil
Hydroxychloroquine
Placebo
Plan Nacional sobre el Sida (PNS) This study aims to assess the efficacy of a daily single dose of tenofovir disoproxil fumarate (TDF), a daily single dose of hydroxychloroquine (HC), a daily single dose of TDF plus HC versus placebo, during 12 weeks in: (1) reducing the incidence of symptomatic disease and (2) reducing clinical severity COVID-19 Start Date: April 1, 2020

Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19

Phase 2

Hydroxychloroquine Sulfate + Azithromycin Rutgers, The State University of New Jersey This is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromycin in order to determine which regimen is more effective. Start Date: April 6, 2020

Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection

Phase 4

Hydroxychloroquine Instituto de Investigación Marqués de Valdecilla The investigators plan to evaluate a strategy of chemoprophylaxis with hydroxyloquine (HCQ) against COVID-19 infection in patients diagnosed with an immunomediated inflammatory disease who are following a treatment with biological agents and / or Jak inhibitors.  Start Date: April 6, 2020

Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-Risk Population (SHARP): A Cluster Randomized Controlled Trial (SHARP COVID-19)

Phase 3

Hydroxychloroquine Sulfate Tan Tock Seng Hospital This cluster randomized trial will evaluate the safety and efficacy of oral HCQ PEP, taken over for 5 days, in reducing the number of infected household contacts of confirmed COVID-19 patients under home quarantine.  Start Date: April 2020

Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)

Phase 3

Hydroxychloroquine + azithromycin Hospital Israelita Albert Einstein The present study will evaluate the effectiveness and safety of the use of hydroxychloroquine combined with azithromycin compared to hydroxychloroquine monotherapy in patients hospitalized with pneumonia by SARS-CoV2 virus. Start Date: March 28, 2020

Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus (Coalition-I)

Phase 3

Hydroxychloroquine + azithromycin Hospital do Coracao Study aims to compared standard of care, hydroxychloroquine plus azythromycin and hydroxychloroquine monotherapy for treatment of hospitalized patients with COVID-19. Start Date: April 6, 2020

Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO (CORIMUNO-VIRO)

Phase 2,3

Sarilumab
Azithromycin
Hydroxychloroquine
Assistance Publique - Hôpitaux de Paris The overall objective of the study is to determine the therapeutic effect and tolerance of Sarilumab in combination with Azithromycin and Hydroxychloroquine, compared to Sarilumab only, patients with moderate, severe pneumonia associated with Coronavirus disease 2019 (COVID-19). Start Date: April 2020

Test and Treat COVID 65plus+ (COVID65plus)

Phase 2,3

Hydroxychloroquine University Hospital Tuebingen Patients over equal or older than 65 years will be treated with a hydroxychloroquine versus placebo reduced loading dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days resulting in a total duration of therapy of 7 days. Start Date: May 1, 2020

The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2

Phase 2,3

Hydroxychloroquine
Remdesivir
Standard of Care
Oslo University Hospital The WHO NOR- COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and standard of care in hospitalized adult patients diagnosed with COVID-19.  Start Date: March 26, 2020

The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment

Phase 2,3

Chloroquine
Nitazoxanide
Ivermectin
Tanta University Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 treatment Start Date: April 17, 2020

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol (FMTVDM)

Phase 2,3

Hydroxychloroquine
Azithromycin
Doxycycline
Clindamycin
Primaquine
Remdesivir
Tocilizumab
Methylprednisolone
Interferon-Alpha2B
Losartan
Convalescent Serum
The Camelot Foundation The purpose of this paper is to make clinicians and researchers aware of this proposed method for investigating the prevalence and severity of CVP - in addition to providing rapid determination of treatment response in each patient, directing treatment decisions; thereby reducing the loss of time, money, resources and patient lives. Start Date: April 11, 2020

The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

Phase 2

Hydroxychloroquine Sulfate University of Pennsylvania This study evaluates the safety and efficacy of hydroxychloroquine in the treatment of COVID-19. Start Date: April then 8, 2020

The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19

Phase 2

Clevudine
Hydroxychloroquine
Bukwang Pharmaceutical The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 120 mg once a day for 14 days (maximum up to 21 days) and of Hydroxychloroquine 200mg twice a day for 14 days (maximum up to 21 days) of administration in patients with moderate COVID-19. Start Date: April 24, 2020

The Vietnam Chloroquine Treatment on COVID-19 (VICO)

Phase 2

Chloroquine Phosphate Oxford University Clinical Research Unit, Vietnam The purpose of the pilot is to develop the study procedures for the randomized controlled trial, including the safe monitoring of patients, to refine the CRF, and to acquire some preliminary data on the safety of chloroquine in those with COVID-19. Start Date: April 1, 2020

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease (RCT)

Phase 3

Hydroxychloroquine
Azithromycin
LCMC Health This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected patients with early moderate and severe disease admitted to the hospital and randomized to one of three arms.  Start Date: April 10, 2020

Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic

Phase 3

Antiviral treatment (Chloroquine, Darunavir/Cobicstat) and prophylaxis Oriol Mitja, Germans Trias i Pujol Hospital The investigators plan to evaluate the efficacy of the 'test and treat' strategy of infected patients and prophylactic chloroquine treatment to all contacts. The strategy entails decentralized COVID-19 testing and starting antiviral darunavir/cobicistat plus chloroquine treatment immediately in all who are found to be infected. Start Date: March 15, 2020

Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

Phase 2

Liponavir/Ritonavir
hydroxychloroquine sulfate
baricitinib
sarilumab
Nova Scotia Health Authority    
Halifax, Nova Scotia, Canada
Investigational medications adjunct to clinical standard of care treatment will be assessed to evaluate safety and effectiveness as an anti-COVID-19 treatment Start Date: April 2020

Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)

Phase 3

Remdesivir
Lopinavir/ritonavir
Interferon Beta-1A
Hydroxychloroquine
Standard of care
Institut National de la Santé Et de la Recherche
Médicale, France
The primary objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19. Start Date: March 22, 2020

Umifenovir in COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial (UAIIC)

Phase 4

Umifenovir
Interferon-β 1a
Lopinavir / Ritonavir
Single Dose of Hydroxychloroquine
Standards of Care
Shahid Beheshti University of Medical Sciences The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Start Date: April 15, 2020

University of Utah COVID-19 Hydrochloroquine Trial

Phase 2

Hydroxychloroquine University of Utah The rationale for this clinical trial is to measure the efficacy and safety of hydroxychloroquine for reducing viral load and shedding in adult outpatients with confirmed COVID-19. Start Date: April 14, 2020

Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)

Phase 3

Hydroxychloroquine Sulfate
Hydroxychloroquine Sulfate + Azythromycin
Apsen Farmacêutica S.A.  
São Paulo, Brazil
Hydroxychloroquine is a drug with great potential treatment, as it can inhibit the pH-dependent steps of replication of various viruses, with a potent effect on SARS-CoV infection and spread. In this way, the present study will evaluate the safety and efficacy of the hydroxychloroquine in patients with symptomatic SARS-Cov2. Start Date: May 4, 2020

Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial

Phase 3

Oseltamivir
Chloroquine
Lopinavir
Ritonavir
Favipiravir
Oseltamivir
Darunavir
Thailand, Rajavithi Hospital A 6-Week Prospective, Open label, Randomized, in Multicenter Study evaluating the efficacy and safety of various combinations of protease inhibitors in the treatment of COVID-19. Start Date: March 15, 2020

Will Hydroxychloroquine Impede or Prevent COVID-19 (WHIP COVID-19)

Phase 3

Hydroxychloroquine Henry Ford Health System The primary objective of this study is to determine whether the use of daily or weekly oral hydroxychloroquine (HCQ) therapy will prevent SARS-CoV-2 infection and COVID-19 viremia and clinical COVID-19 infection. Start Date: April 7, 2020
Publications
Title Authors Journal Date Summary
Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19 Meo SA, Klonoff DC, Akram J. European Review for Medical and Pharmacological Sciences April 24, 2020 A review of the treatment of chloroquine and hyroxychloroquine for COVID-19 infections. The results suggest that these drugs have efficacy for treating COVID-19. 
Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19 Ruamviboonsuk P., Lai TYY., Chang A., Lai CC., Mieler WF., Lam DSC. The Asia-Pacific Journal of Ophthalmology  Mar-Apr 2020 Discusses the potential of chloroquine to cause retinal damage when used in high doses over a short period of time for COVID-19 treatment.

 

Convalescent Plasma 

Treatment Description
Antibody rich plasma provided by COVID-19 convalescent patients (Tiberghien et al 2020) and given to patients infected with SARS-CoV-2
Has been used previously for 1918 pandemic flu, measels, MERS-CoV, SARS, and Ebola (Rubin R., 2020)
US Food and Drug Administration will facilitate access to convalescent plasma for the treatment of COVID-19 (Rubin R. 2020)
Clinical Trials
Name of Study Intervention Location Description Progress

A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications

Phase 2

Convalescent Plasma Max Super Speciality hospital, Saket
New Delhi, Delhi, India
We designed this phase II, open label, randomized clinical trial with the primary objective to assess the safety and efficacy of the therapy in the second stage. Start Date: May 9, 2020

A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection

Phase 2

anti-SARS-CoV-2 convalescent plasma Froedtert Hospital
Milwaukee, Wisconsin, United States
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19. Start Date: May 11, 2020

Anti COVID-19 Convalescent Plasma Therapy

Early Phase 1

anti-SARS-CoV-2 convalescent plasma Orthosera Kft. Our hypothesis is that convalescent plasma transfusion from healthy donors who recovered from SARS CoV-2 is able to reduce the cytokine storm in addition to replenish the patient's own antibodies in the acutely infected phase of the disease. Start Date: April 14, 2020
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19 Convalescent Plasma Shanghai Public Health Clinical Center The study is to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of COVID-19 pneumonia. Start Date: February 1, 2020
Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program Convalescent Plasma   This is an expanded access treatment protocol to treat up to 100 patients with severe or life-threatening, laboratory confirmed COVID-19 with COVID-19 convalescent plasma.  

Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection

Phase 1,2

 Hyperimmune plasma
Hidroxicloroquina + Azitromicina
Lopinavir/ritonavir + Interferon β-1b + Hidroxicloroquina
Hospital Unversitario Virgen Macarena
Sevilla, Spain
Phase I / II multicentre, randomized and controlled clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection. Start Date: April 2020
Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients RFMN - Clinical Research Center for Rare Diseases
Ranica, BG, Italy
ASST HPG23 - Unit of Nephrology
Bergamo, Italy
ASST Papa Giovanni XXIII - Microbiology and Virology Unit
Bergamo, Italy
Asst Pg23 - S.I.M.T
Bergamo, Italy
ASST-PG23 - Intensive Care Unit
Bergamo, Italy
A pilot study aimed to explore whether the infusion of antibodies obtained with one single DFPP procedure from voluntary convalescent donors could offer an effective and safe therapeutic option for critically ill patients with severe coronavirus (COVID-19) pneumonia requiring mechanical ventilation. Start Date: April 15, 2020
Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia Convalescent SARS COVID-19 plasma
Placebo
  A multicenter randomized, double-blind, placebo-controlled clinical trial of Convalescent SARS COVID-19 plasma versus Placebo to evaluate the effect between arms on an ordinal score of six mutually exclusive categories of clinical status at day 30 after study initiation. Start Date: May 15, 2020

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

Phase 2

Convalescent Plasma Hackensack Meridian Health This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection. Start Date: April 9, 2020

Convalescent Plasma Collection and Treatment in Pediatrics and Adults

Phase 3

Convalescent Plasma WVU Medicine
Morgantown, West Virginia, United States
This is a prospective study, involving contacting potential plasma donors and the use of their plasma to help fight off infections of those suffering from COVID19 in accordance to collection guidelines for plasma and FDA IND requirement Start Day: April 16, 2020

Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia

Phase 2

Plasma Hospital Universitario José E. Gonzalez
Monterrey, Nuevo Leon, Mexico
Randomized clinical trial comparing convalescent plasma to best available therapy (BAT) for the treatment of severely ill and critically ill patient with COVID-19. Start Date: April 27, 2020
Convalescent Plasma for COVID-19 Blood plasma   The purpose of this proof of concept study is to provide COVID-19 convalescent plasma to patients with moderate to severe COVID-19  Start Date: April 27, 2020

CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) (CONCOR-1)

Phase 3

Convalescent plasma McMaster University (Hamilton Health Sciences Corporation) The objective of the CONCOR-1 trial is to determine the efficacy of transfusion of COVID-19 convalescent plasma to adult patients admitted to hospital with COVID-19 infection at decreasing the frequency of in-hospital mortality in patients hospitalized for COVID-19. Start Date: April 27, 2020

Convalescent Plasma for Ill Patients by COVID-19

Phase 1,2

Convalescent Plasma Hospital Del Issste Regional En Guadalajara Jalisco
Guadalajara, Jalisco, Mexico
Secretaria de Salud Del Estado de Sonora, Hospital General Del Estado
Hermosillo, Sonora, Mexico
Hospital Central Norte Pemex
Mexico City, Mexico
hospital general de Mexico
Mexico City, Mexico
The present study will try to respond first in an initial phase, what is the minimum effective dose necessary of convalescent plasma for getting better in severly ill (not intubated) or very severely ill (intubated) patients. Start Date: May 2020

Convalescent Plasma for Patients With COVID-19

Phase 2

Convalescent Plasma Henry Ford Hospital
Detroit, Michigan, United States
Pilot study of tolerability and efficacy of transfusion of 200mL of convalescent plasma in patients with COVID-19 respiratory disease. Start Date: May 4, 2020

Convalescent Plasma for Patients With COVID-19: A Pilot Study (CP-COVID-19)

Phase 2

Plasma Universidad del Rosario The process is based on obtaining plasma from patients recovered from COVID-19 in Colombia, and through a donation of plasma from the recovered, the subsequent transfusion of this to patients infected with coronavirus disease (COVID-19). Start Date: April 1, 2020

Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study (CP-COVID-19)

Phase 2,3

Plasma, Hydroxychloroquine, Azithromycin Universidad del Rosario The process is based on obtaining plasma from patients recovered from COVID-19 in Colombia, and through a donation of plasma from the recovered, the subsequent transfusion of this to patients infected with coronavirus disease (COVID-19). Start Date: April 1, 2020
Convalescent Plasma for the Treatment of Patients With COVID-19
 
COVID-19 Convalescent Plasma Multiple sites in Colorado, United States The primary objective of this expanded access program is to provide COVID-19 convalescent plasma to patients with moderate to severe or life-threatening manifestations of COVID-19, or documented to be at high risk of developing such manifestations.  

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia

Phase 2

Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma University of Virginia Medical Center
Charlottesville, Virginia, United States
University of Virginia
Charlottesville, Virginia, United States
This is a single arm phase II trial to assess efficacy and confirm safety of infusions of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms,with or without confirmed interstitial COVID-19 pneumonia by chest Xray or CT. A total of 29 eligible subjects will be enrolled to receive anti-SARS-CoV-2 plasma. Start Date: May 5, 2020

Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study

Phase 1,2

SARS-CoV-2 convalescent plasma Danderyd Hospital
Danderyd, Stockholm, Sweden
Karolinska University Hospital
Stockholm, Sweden
The proposed study thus aims to treat a high risk population identified by having viremia irrespective of but hopefully before they develop pulmonary injury such that they require supplementary oxygen therapy.  Start Date: May 7, 2020

Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure

Early Phase 1

Multiple Doses of Anti-SARS-CoV-2 convalescent plasma 8700 Beverly Blvd. Los Angeles, California, United States    Johns Hopkins University Baltimore, Maryland, United States   University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States This study will assess the feasibility of administering multiple doses of convalescent plasma (from people who have recovered form SARS-CoV-2) to Covid-19 positive patients in the Intensive Care Unit receiving mechanical ventilation. Start Date: May 2020

Convalescent Plasma in the Treatment of COVID 19

Phase 2

Convalescent Plasma Saint Francis Care The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection. Start Date: April 10, 2020

Convalescent Plasma Therapy From Recovered Patients to Treat Severe SARS-CoV-2 Disease (CONCOVID Study) (ConCoVid)

Phase 2,3

Convalescent Plasma Bart Rijnders, Erasmus Medical Center With no proven effective therapy against COVID-19, this protocol will evaluate the therapeutic potential of therapy with convalescent plasma from COVID-19 recovered donors. Start Date: April 1, 2020

Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients (ConPlas-19)

Phase 2

Blood and derivatives, Standard of Care Puerta de Hierro University Hospital A multi-center, randomized, clinical trial with two arms to study the efficacy and safety of passive immunotherapy with CP compared to a control of standard of care (SOC). Start Date: April 3, 2020

Convalescent Plasma to Limit Coronavirus Associated Complications

Phase 2

Convalescent Plasma Mayo Clinic Researchers are trying to assess the treatment potential and safety of anti-SARS-CoV-2 convalescent plasma in patients with acute respiratory symptoms with confirmed COVID-19. Start Date: April 1, 2020

Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients

Phase 2

Convalescent Plasma Montefiore Medical Center
Bronx, New York, United States
NYU Langone Health
New York, New York, United States
This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation. Start Date: April 17, 2020
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications (CSSC-004)
 
Phase 2
SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor   To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding. Start Date: May 11, 2020
Convalescent Plasma Trial in COVID -19 Patients convalescent plasma with antibody against SARS-CoV-2 Royal College of Surgeons in Ireland - Bahrain
Manama, Bahrain
The objective of this pilot study is to compare plasma therapy using convalescent plasma with antibody against SARS-CoV-2 to usual supportive therapy in COVID-19 patients with pneumonia and hypoxia, and to determine if the clinical course is improved.  Start Date: April 19, 2020

Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia

Phase 3

Plasma from COVID-19 convalescent patient
Human immunoglobulin
Centenario Hospital Miguel Hidalgo
Aguascalientes, Mexico
Objective: To assess the safety and efficacy of the administration of Convalescent plasma vs human immunoglobulin in critically ill patients with COVID-19 infection. Start Date: May 6, 2020

Convalescent Plasma vs. Placebo in Emergency Room Patients With COVID-19

Phase 2

Convalescent Plasma Stanford University
Stanford, California, United States
This study will evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma (convalescent plasma) versus control (standard plasma) in patients with COVID-19 respiratory symptoms. Start Date: May 2020

Convalescent Plasma vs. Standard Plasma for COVID-19

Phase 1,2

Convalescent Plasma, Standard Donor Plasma Stony Brook University The purpose of this study is to find out if transfusion of blood plasma containing antibodies against COVID-19 (anti-SARS-CoV-2), which were donated from a patient who recovered from COVID-19 infection, is safe and can treat COVID-19 in hospitalized patients. Start Date: April 8, 2020

COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma

Phase 2

Convalescent Plasma Centro de Hematología y Medicina Interna
Puebla, Mexico
Injecting convalescent plasma into patients with severe forms of COVID-19 shortens the period of risk while the patient produces the antibodies. Start Date: April 13, 2020

COVID-19 Convalescent Plasma
Early Phase 1

anti-SARS-CoV-2 convalescent plasma University of Chicago The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life-threatening COVID-19. Start Date: April 30, 2020
COVID-19 Plasma Collection Plasma Donation Thomas Jefferson University The purpose of this study is to describe the process for identifying and collecting convalescent plasma from donors previously infected with the virus. Start Date: April 13, 2020

CoVID-19 Plasma in Treatment of COVID-19 Patients

Early Phase 1

Convalescent COVID-19 Plasma The Christ Hospital
Cincinnati, Ohio, United States
The investigators propose to evaluate intravenous administration of convalescent plasma (CP) obtained from COVID19 survivors in patients requiring hospitalization for symptomatic "high risk" COVID19 disease as reflected by the presence of elevated hsTPN. Start Date: April 2020

COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)

Phase 2,3

Convalescent Plasma Fundacion Arturo Lopez Perez
Providencia, Santiago, Chile
This is a collaborative, 4 arms , non randomized clinical trial assessing the use of Convalescent Plasma from COVID-19 recovered donors to be used in oncological and non-oncological patients with current severe COVID-19 infection or in patients with risk factors of major complications secondary to COVID-19 infection Start Date: April 7, 2020
Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression. (LIFESAVER)
Phase 2,3
COVID-19 Convalescent Plasma Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, RM, Italy
Ospedale SS Annunziata
Chieti, Italy
Istituto Nazionale Malattie Infettive Lazzaro Spallanzani
Rome, Italy
The investigators hypothesize that transfusing convalescent plasma (containing neutralizing antibodies) at an early phase of COVID-19 infection could prevent or switch off the persistent inflammatory response elicited by the virus. Start Date: May 15, 2020

Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome

Phase 2,3

Convalescent Plasma Dr. Cipto Mangunkusumo General Hospital
Jakarta, DKI Jakarta, Indonesia
St. Carolus Hospital
Jakarta, DKI Jakarta, Indonesia
PELNI Hospital
Jakarta, DKI Jakarta, Indonesia
The use of convalescent plasma has been approved by the US Food and Drug Administration (FDA) through the scheme of emergency investigational new drug (eIND). This method has been used as the treatment in several outbreak or plague cases over the years, such as the flu epidemic in 1918, polio, measles, mumps, SARS (severe acute respiratory syndrome), EVD (Ebola virus disease) and MERS (middle-eastern respiratory syndrome) and this treatment shows better outcome.  Start Date: May 11, 2020

Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19 (CSSC-001)

Phase 2

Anti- SARS-CoV-2 Plasma, SARS-CoV-2 non-immune Plasma Johns Hopkins University Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28. Start Date: May 1, 2020
Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection
 

Phase 2 

COVID-19 convalescent plasma Hospital Clínico Universidad Católica
Santiago, Chile
This study is an open-label randomized trial in which patients with high risk of COVID19-associated respiratory failure will be randomized to early treatment with convalescent plasma (< 7 days from symptoms start) or at early signs of respiratory failure or prolonged hospitalization. COVID-19 convalescent plasma will be collected from individuals according to the institutional protocol. Start Date: May 4, 2020

Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia

Phase 3

Convalescent anti-SARS-CoV-2 plasma
Sarilumab
Baricitinib
Hydroxychloroquine
Placebo
Various Locations in Denmark CCAP is an investigator-initiated multicentre, randomized, double blinded, placebo-controlled, multi-stage trial, which aims to assess the safety and efficacy of novel treatment option of moderate-severe COVID-19. Start Date: April 20, 2020

Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients

Phase 2

Convalescent Plasma Transfusion Institute of Liver and Biliary Sciences, India
Maulana Azad medical College
New Delhi, Delhi, India
We have planned a randomized controlled trial to assess the efficacy of convalescent plasma from recovered COVID-19 infected patients in COVID-19 infected sick patients. Start Date: April 14, 2020
Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. (PLASCOSSA)
 
Phase 3
Transfusion of SARS-CoV-2 Convalescent Plasma HIA Percy
Clamart, France
HIA Laveran
Marseille, France
HIA Bégin
Saint-Mandé, France
HIA Sainte Anne
Toulon, France
PlasCoSSA is a randomized, controlled, triple-blinded, parallel clinical trial. This study tests the efficacy of convalescent plasma transfusion therapy in the early care of COVID-19 hospitalized patients outside intensive care units. Start Date: May 2020

Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort (CORIPLASM)

Phase 2

Transfusion of COVID-19 convalescent plasma Hôpitaux de Paris The objective of COVIPLASM trial (a nested trial in the CORIMUNO-19 COHORT) is to study the efficacy of convalescent plasma to treat SARS-COV2 infected patients. Start Date: April 14, 2020

Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children

Phase 2

Convalescent Plasma Various Children's Hospitals in Canada This is a multicentered, open-label, randomized controlled Phase 2 trial to evaluate the safety and efficacy of providing human coronavirus-immune convalescent plasma as treatment for COVID-19 disease in hospitalized children in the context of the COVID-19 pandemic. Start Date: May 1, 2020
Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy High-Titer COVID-19 Convalescent Plasma (HT-CCP)
Standard Plasma (FFP)
  In this study, investigators will determine whether the early addition of HT-CCP to standard treatment improves the clinical outcome (as assessed by the Modified WHO Ordinal Scale) of patients with COVID-19 who are hospitalized but not yet in moderate or severe ARDS. Start Date: April 2020
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 COVID-19 Convalescent Plasma Mayo Clinic (Various Locations around the US) This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease. Start Date: April 2020
Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19 COVID-19 convalescent plasma Tulane Medical Center
New Orleans, Louisiana, United States
This is a single-arm feasibility study to assess the safety and efficacy of anti-SARS-CoV-2 convalescent plasma (CP) in

intubated, mechanically ventilated patients with confirmed COVID-19 pneumonia by chest X-ray or chest CT.
hospitalized patients with acute respiratory symptoms between 3 and 7 days after the onset of symptoms, with COVID-19.
 

Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)

Phase 1

Anti-SARS-CoV-2 Human Convalescent Plasma   The purpose of this study is to evaluate the safety of administration of plasma containing antibodies to the SARS-CoV-2 virus (i.e., convalescent plasma) and if it is able to prevent disease or lessen the severity of disease in individuals who are at high risk of developing COVID-19 due to a recent exposure.  Start Date: May 18, 2020
Hyperimmune Plasma for Critical Patients With COVID-19 (COV19-PLASMA) hyperimmune plasma Foundation IRCCS San Matteo Hospital We plan to treat critical Covid-19 patients with hyperimmune plasma. Start Date: March 17, 2020

Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19

Phase 2

Inactivated convalescent plasma Multiple sites in Columbia This study consists of obtaining convalescent plasma by means of apheresis, from recovered donors, who meet the eligibility criteria to donate.  Start Date: May 20, 2020
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial Convalescent Plasma Mazandaran University of Medical Sciences In this study the investigators aim to determine the effect of Convalescent Plasma on COVID-19 patients Outcome through a Clinical Trial. Start Date: March 28, 2020

Passive Immunity Trial of Nashville II for COVID-19

Phase 3

pathogen reduced SARS-CoV-2 convalescent plasma Vanderbilt University Medical Center
Nashville, Tennessee, United States
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting.  Start Date: April 24, 2020
Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial (REP-COVID)
 
Phase 2
Plasma exchange Hospital Clinic i Provincial de Barcelona
Barcelona, Spain,
Plasma exchanges with 5% human albumin (2/3 of the exchanged plasma volume) and fresh frozen plasma (FFP: 1/3) in patients with quick <50% or only with 5% albumin in patients with quick of 50% or more. We will exchange between 1.2 and 1.5 plasma volumes, that will vary according to sex, weight, height and hematocrit. Start Date: April 29, 2020
Plasma Rich Antibodies From Recovered Patients From COVID19 (PRA-001) Antibody-Rich Plasma from COVID-19 recovered patients Ain Shams University Prospective interventional study, single arm of purified convalescent plasma transfusion as an add on therapy for the standard of care treatment (national guideline), Oseltamivir, and hydroxychroquine  ± Azithromycin daily for 5 days Start Date: April 20, 2020

Plasma Therapy of COVID-19 in Critically Ill Patients

Phase 2

Convalescent Plasma (anti-SARS-CoV-2 plasma)
Non-convalescent Plasma (control plasma)
Columbia University Irving Medical Center/NYP
New York, New York, United States
This randomized blinded phase 2 trial will assess the efficacy and safety of Anti-SARS-CoV-2 convalescent plasma among adults with severe COVID-19.  Start Date: April 21, 2020

Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19

Phase 2

convalescent plasma from recovered COVID 19 donor King Fahad Specialist Hospital Dammam We are proposing to test the therapeutic potential of convalescent plasma (from patients who have fully recovered from COVID-19) in treating patients with serious COVID-19 disease or those who are at risk of developing a serious disease based on their comorbidities profile.  Start Date: April 12, 2020

Safety in Convalescent Plasma Transfusion to COVID-19

Phase 1

Convalescent Plasma Hospital San Jose Tec de Monterrey The investigator will evaluate the safety and efficacy of plasma obtained from convalescent individuals with proven novel SARS-CoV-2 virus infection, diagnosed with coronavirus-19-induced disease and symptom-free for a period of not less than 10 days in the treatment of individuals infected with COVID-19. Start Date: April 15, 2020
SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP) SARSCoV2 Convalescent Plasma AdventHealth Orlando
Orlando, Florida, United States
The purpose of this trial is to provide expanded access to SARSCoV2 convalescent plasma (EAP) collected from matched donors as described to patients with severe or life-threatening illness owing to COVID-19.  

Study Testing Convalescent Plasma vs Best Supportive Care

Phase 1

high-titer anti-Sars-CoV-2 plasma Baylor Research Institute The study aims to evaluate the efficacy of convalescent plasma in the treatment of COVID-19.  Start Date: April 1, 2020
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) Anti-Sars-CoV-2 Convalescent Plasma   This treatment protocol is designed to provide a treatment option for patients diagnosed with severe or life-threatening COVID-19 or judged by the subinvestigator (treating physician) to be at high risk of progressing to severe or life threatening disease  
Publications
Title Authors Journal Date PID Summary
Convalescent Plasma in Covid-19: Possible Mechanisms of Action Rojas M., Rodriguez Y., et al. Autoimmunity Reviews May 5, 2020 32380316 This article discusses the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system and immunomodulation of a hypercoagulable state.
Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Zhang B., et al. Chest March 31, 2020 32243945 Herein, we present four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma.
Deployment of Convalescent Plasma for the Prevention and Treatment of COVID-19 Bloch E. M., et al. Journal of Clinical Investigation April 7, 2020 32254064 We provide an overview of convalescent plasma, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource.
Use of Convalescent Plasma Therapy in Two COVID-19 Patients With Acute Respiratory Distress Syndrome in Korea Ahn J. Y., Sohn Y., Lee S. H., et al. Journal of Korean Medical Science April 13, 2020 32281317 We describe two cases of COVID-19 treated with convalescent plasma infusion. Both patients presented severe pneumonia with acute respiratory distress syndrome and showed a favorable outcome after the use of convalescent plasma in addition to systemic corticosteroid. To our knowledge, this is the first report of the use of convalescent plasma therapy for COVID-19 in Korea.
Treatment With Convalescent Plasma for COVID-19 Patients in Wuhan, China Ye M., Fu D., Ren Y., et al. Journal of Medical Virology April 15, 2020 32293713 In order to evaluate the efficacy of convalescent plasma therapy in COVID-19 patients, we did this timely descriptive study. 6 laboratory confirmed COVID-19 patients were enrolled and received the transfusion of ABO-compatible convalescent plasma.
Effectiveness of Convalescent Plasma Therapy in Severe COVID-19 Patients Duan K., Liu B., Li C., et al. Proceedings of the National Academy of Sciences of the United States of America April 28, 2020 32253318  In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents.
Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients Zeng Q. L., Yu Z. J., Gou J. J., et al. The Journal of Infectious Diseases April 29, 2020 32348485 In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier.
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Shen C., Wang Z., Zhao F., et al. The Journal of the American Medical Association March 27, 2020 32219428 In this uncontrolled case series of 5 critically ill patients with COVID-19 and acute respiratory distress syndrome (ARDS), administration of convalescent plasma containing neutralizing antibody was followed by an improvement in clinical status.
Collecting and Evaluating Convalescent Plasma for COVID-19 Treatment: Why and How? Tiberghien P., Laballerie X., Morel P., Gallian P., Lacombe K., Yazdanpanah Y. Vox Sanguinis April 2, 2020 32240545 Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking.

 

Favipiravir

Drug Description
Broad spectrum inhibitor of viral RNA polymerase (Furata et al 2020)
Discovered for the use against influenza virus 
RNA-dependent RNA polymerase (RdRp) is conserved among vairus types of RNA viruses (Furata et al 2020)
Clinical Trials
Name of Study Intervention Location Description Progress

A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe

Phase 3

Favipiravir
Hydroxychloroquine
Azithromycin
Zinc Sulfate
Standard of care management

Chelsea and Westminster Hospital
London, United Kingdom
 

West Middlesex University Hospital
London, United Kingdom

A prospective, randomised, open label study of the combined use of azithromcycin, hydroxychloroquine, zinc and standard clinical care verses favipiravir and standard clinical care verses standard clinical care alone. Start Date: May 1, 2020

A Real-life Experience on Treatment of Patients With COVID 19

Phase 2,3

Chloroquine

Favipiravir

Nitazoxanide

Ivermectin

Niclosamide

Tanta University COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin. April 15, 2020

Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19

Phase 3

Favipiravir

Placebo

Asst Fatebenefratelli Sacco

Milano, Italy, 20157

This study evaluates treatment with Favipiravir combined with supportive care for adult patients with COVID-19-moderate type. Start Date: March 25, 2020
Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive Favipiravir Multiple Locations in China To investigate the mechanism, clinical outcome and therapeutic efficacy with favipiravir of Corona Virus Disease 2019 patients whose nucleic acids changed from negative to positive. Start Date: April 1, 2020

Efficacy and Safety of Favipiravir in Management of COVID-19 (FAV-001)

Phase 3

Favipiravir

Standard of Care

Ain Shams University Randomized controlled interventional trial (Clinical Trial) phase 3 to assess the safety and efficacy of favipiravir versus the standard care therapy in the treatment of patients with COVID-19. Start Date: April 20, 2020

Efficacy of Faviprevir in COVID-19 Treatment

Phase 2,3

Favipiravir
Placebo
Tanta University
Tanta, Egypt
Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 treatment Start Date: April 17, 2020
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19

Bromhexine Hydrochloride Tablets

Arbidol Hydrochloride Granules

Recombinant Human Interferon α2b Spray

Favipiravir

China, Zhejiang   

The Second AffIliated Hospital of Wenzhou Medical University

Compare the efficacy and safety of Bromhexine Hydrochloride Tablets combined with standard treatment/ standard treatment in patients with suspected and mild, or common novel coronavirus pneumonia (COVID-19). Start Date: February 16, 2020
Favipiravir Combined With Tocilizumab in the Treatment of Coronavirus Disease 2019

Favipiravir Combined With Tocilizumab

Favipiravir

Tocilizumab

Gilead Sciences (Stanford (CA), Newport Beach (CA), Seattle (WA), Everett (WA), Hong Kong, South Korea, Singapore, Taiwan) The purpose of this study is to evaluate the efficacy and safety of favipiravir combined with tocilizumab in the treatment of coronavirus disease 2019. Start Date: March 8, 2020
Favipiravir in Hospitalized COVID-19 Patients (FIC)
 
Phase 4

Favipiravir

Hydroxychloroquine

Shahid Modarres Hospital

Shahid Beheshti

University of Medical Sciences and Health Services

Tehran, Iran, Islamic Republic of

The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. Start Date: April 20, 2020

Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19

Phase 2

Favipiravir Stanford University The objective of this study is to evaluate the efficacy of oral favipiravir compared with SOC in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease. Start Date: April 2020
Safety and Efficacy of Hydroxychloroquine + Favipiravir Drug Regimen in Comparison With Hydroxychloroquine + Kaletra on the Need for Intensive Care Unit Treatment in Patients With COVID-19

Favipiravir

Hydroxychloroquine

Kaletra

    Start Date: March 29, 2020

Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19

Phase 2

Favipiravir + Standard of Care


Standard of Care

Brigham and Women's Hospital
Boston, Massachusetts, United States

 

Massachusetts General Hospital
Boston, Massachusetts, United States

 

UMass Memorial Health Care
Worcester, Massachusetts, United States

To determine the effect of favipiravir + SOC v. SOC on COVID-19 viral clearance. Start Date: April 17, 2020

Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19)

Phase 3

Hydroxychloroquine
Imatinib
Favipiravir
Telmisartan

Bordeaux university Hospital
 

Bordeaux, France

This trial will estimate the efficacy and tolerance of several experimental treatments to prevent hospitalization or death in outpatients aged 65 years or above with Symptomatic SARS-CoV-2 Infection (COVID-19). Start Date: April 15, 2020
Publications
Title Authors Journal Date Summary
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study Cai Q., Yang M., et al. Engineering (Beijing) March 18, 2020 Examine efficacy of Favipiravir vs. Lopinavir/Ritonavir for the treatment of COVID-19. Favipiravir showed better results for disease progression and viral clearance.

 

Other

Drug/Treatment Descriptions

Meplazumab

Humanized IgG2 monoclonal antibody against CD147
Inhibits SARS_CoV-2 replication and virus-inducced cytopathic effect in Vero E6 cells (Bian et al 2020)

Arbidol

ethyl-6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-indole-3-carboxylate hydrochloride monohydrate
Broad -specturm antiviral with demonstrated activity against both enveloped and non-enveloped viruses (Boriskin et al 2008)

Darunavir/Cobicistat

Hasn't been proven effective 
HIV protease inhibitor (Kakuda et al 2015)

 mRNA-1273

Manufactured by ModernaTX, Inc. 
A novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine (Wang et al 2020)
Encodes for a full length prefusion stabilized spike (S) protein of 2019 novel coronavirus (Wang et al 2020)
Clinical Trials
Name of Study Intervention Location Description Progress

Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia

Phase 1,2

Meplazumab for Injection Shaanxi Tangdu Hospital Xi'an, Shaanxi, China According to the results of nonclinical study of humanized Meplazumab for Injection, a single dose will be used for the treatment. Each subject will be evaluated the therapeutic effect within 28 days after the first administration, and to determine the preliminary therapeutic effect, safety and tolerability of humanized Meplazumab for Injection. Start Date: February 3, 2020

Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus

Phase 4

Arbidol Hydrochloride No Locations Provided  380 eligible patients with pneumonia diagnosed with 2019-ncov infection were randomly assigned to one of two treatment groups at a 1:1 ratio. Patients will receive one of two treatment regimens: A .Abidor tablets + basic treatment B. basic treatment Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days Basic treatment :The basic treatment used by the investigator was based on the condition of the patient. Start Date: February 7, 2020

Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV

Phase 3

Darunavir, Cobicistat Shanghai Public Health Clinical Center Shanghai, China There is no vaccine or antiviral treatment for human coronavirus, so this study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of pneumonia caused by the 2019 novel coronavirus Start Date: January 30, 2020

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection

Phase 1

mRNA-1273 Emory Children's Center - Pediatric Infectious Diseases Decatur, Georgia, United States   Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases  Seattle, Washington, United States This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of 2019-novel coronavirus (nCoV).  Start Date: March 3, 2020
Publications
Arbidol
Title Authors Journal Date Summary
Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ? Vankadari N. International Journal of Antimicrobial Agents April 28, 2020 This article shows the target and mechnism of action for Arbidol. It provides the structural and molecular dynamics for how Aribidol can target SARS-CoV-2. 

 

Tocilizumab
Title Authors Journal Date PID Summary
Off-label Use of Tocilizumab for the Treatment of SARS-CoV-2 Pneumonia in Milan, Italy
 
Morena, et al. European Journal of Internal Medicine May 21, 2020 32448770  In this open-label prospective study we describe clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab intravenously.
Tocilizumab for the Treatment of Severe Coronavirus Disease 2019
 
Alattar R., et al. Journal of Medical Virology May 5, 2020 32369191 This was a retrospective review of patients with laboratory-confirmed severe COVID-19 who received tocilizumab and completed 14 days of follow up.
Tocilizumab Treatment in COVID-19: A Single Center Experience
 
Luo P., Liu Y., Qiu L., Liu X., Liu D., Li J. Journal of Medical Virology April 6, 2020 32253759 In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients.
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Klopfenstein, T. et al. Med Mal Infect. May 6, 2020 32387320 Tocilizumab may reduce ICU admission and mortality of SARS-CoV-2 pneumonia cases.
Effective Treatment of Severe COVID-19 Patients With Tocilizumab
 
Xu X., et al. Proceedings of the National Academy of Sciences of the United States of America May 19, 2020 32350134 This study aimed to assess the efficacy of tocilizumab in severe patients with COVID-19 and seek a therapeutic strategy. 

 

Additional COVID-19 Related Resources

 

This page is sponsored by Dr. Timothy Henrich and the Henrich Lab

For additional questions please contact Tim at [email protected].  

If you are interested in providing additional resources please contact Joanna at [email protected].